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Summary
Objective: To estimate the rate of optimal response to antiretroviral therapy and its predictors in
Colombia.
Methods: A retrospective cohort study was performed. The medical records of all patients at
three major HIV clinics in different areas of Colombia, South America, were reviewed. Eligible
patients met the following criteria: (1) viral load test available while on therapy; and (2) patients
must have been on a stable first antiviral regimen for at least 1 year (48 weeks). Optimal virologic
response was defined as a viral load <400 copies/ml.
Results: Two hundred and twenty patients were eligible for the study. The optimal virologic
response rate was 40% (95% confidence interval 34—46%). Younger age ( p = 0.02) and western
region of the country (p = 0.026) were the only significant predictors of non-optimal response in
bivariate analysis. Multivariate logistic regression analysis confirmed younger age ( p = 0.0054)
and geographic area ( p = 0.0468) as independent predictors of non-optimal response.
Conclusions: The optimal response rate in some areas of Colombia seems lower than that
reported for other areas of the developing world. Poorer virologic responses were observed in
younger patients and in those from the western region of the country.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.§ Presented in part at the 12th Conference on Retrovirus and
Opportunistic Infections, Boston, MA, USA, February 2005 (Abstract
620).
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HIV infection is a major public health problem in Colombia.
By 2002, it was estimated that 170 000 people were living
with HIV/AIDS in Colombia, the highest number of cases for
the Andean sub-region according to the Pan American HealthPublished by Elsevier Ltd. All rights reserved.
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nization (WHO) and UNAIDS, the estimated number of HIV-
infected persons in Colombia was between 170 000 and
220 000 in 2005. The estimated prevalence of HIV for the
population aged 15 to 49 years is 0.7% and it is projected to be
1.5% by the year 2015.2 According to the National Statistics
Administrative Department (Departamento Administrativo
Nacional de Estadı´stica, DANE), AIDS is the third leading
cause of death for people between the ages of 15 and 49
years, surpassed only by homicide and transport accidents.3
The Obligatory Health Plan (Plan Obligatorio de Salud,
POS), established by law in 1993, includes HIV/AIDS on its list
of diseases that require high-cost treatments. This plan
mandates the free provision of antiretroviral therapy
(ART) by Health Promoting Entities (Entidades Promotoras
de Salud, EPS).4 As a result, 72% of the total antiretroviral
treatments in Colombia are provided by one of the EPS.
SaludCoop EPS is the largest EPS in Colombia. It began
operations in 1995 and has shown rapid growth and geogra-
phical expansion. By the end of 2003, the total number of
users affiliated to SaludCoop EPS was estimated at around 5
million. This EPS has several hospitals and clinics across the
Colombian territory.
In 2005, it was estimated that 12 000 people were receiv-
ing antiretroviral therapy in Colombia, which corresponded
to about 50% of those who required it.2 The Colombian
medication market includes both generic medications and
original compounds; generic medications are produced by
local and international pharmaceutical companies. In order
to access the Colombian market, medications require
approval by the National Institute of Food and Medication
Surveillance (Instituto Nacional de Vigilancia de Medicamen-
tos y Alimentos, INVIMA). Of note, despite approval by the
INVIMA, only some of the antiretrovirals marketed in Colom-
bia are included in the WHO prequalification list.5 This
situation, as well as anecdotal failure reports, contributes
to some skepticism among patients and physicians towards
the quality of selected generic medications. However, noFigure 1 Map of Colombia showing the cities where the three H
proportion of HIV cases (using the national number of HIV cases (170
cases are depicted for each city.definitive evidence is available in Colombia to state that the
marketed generic medications are inferior to the original
compounds. The EPS are autonomous in deciding which types
of medications (generic vs. original) are provided to their
affiliated patients.
Although the Obligatory Health Plan (POS) favors universal
access to ART for Colombian patients infected with HIV, the
provision of antiretrovirals has not been paired with pro-
grams to ensure their appropriate use. Issues of concern
related to HIV care in Colombia include the scarcity of
adherence programs, the restricted expertise of healthcare
providers, and the proliferation of pharmaceutical compa-
nies marketing generic medications.
Data regarding optimal ART use in Colombia are limited.
The purpose of this study was to determine the optimal
response rate to first ART, and to establish possible predictors
of non-optimal response. Identification of modifiable predic-
tors of non-optimal response may result in improvements in
care for Colombian patients infected with HIV.
Methods
We performed a retrospective cohort study by reviewing
medical records of all patients at three HIV clinics in different
areas of Colombia (northern, western, and central regions).
These clinics cover HIV patients from three major Colombian
cities (Barranquilla, Medellı´n, and Bogota´, respectively), and
follow approximately 1200 patients infected with HIV.
Figure 1 shows the geographic location and the 2003 esti-
mated number of HIV cases for each of these cities. These
cities include three of the four cities (Bogota´, Cali, Medellı´n
and Barranquilla) with the largest total populations, as well
as the largest numbers of HIV cases in the country.1 Patients
were considered eligible for the study if: (1) viral load testing
was available while on ART; and (2) the patient had been on a
first ART regimen for at least 1 year (48 weeks). All patients
were affiliated to SaludCoop EPS, the largest Health Promot-
ing Entity in Colombia.IV clinics used for data collection are located. The estimated
000) as the denominator) and the estimated absolute number of
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Table 1 Predictors of non-optimal virologic response; bivariate analysis
Categoric variables Optimal response
n (%)
Non-optimal
response n (%)
Risk ratio (95% CI) p Value (Chi-square
or Fisher’s)
Male sex (n = 191) 75 (39.3) 116 (60.7) 1.17 (0.81—1.7) 0.35
Western region (n = 109) 36 (33) 73 (66) 1.28 (1.03—1.6) 0.026
Vertical transmission (n = 6) 0 (0) 6 (100) 1.72 (1.53—1.93) 0.08
Baseline viral load >100 000 (n = 102) 33 (35.9) 69 (64.1) 1.08 (0.86—1.36) 0.51
Baseline CD4 <200 (n = 85) 36 (42.4) 49 (57.6) 1.14 (0.9—1.44) 0.28
Numeric variables Optimal response
Median (range)
Non-optimal response
Median (range)
p Value
(Wilcoxon)
Baseline viral load (copies) 74 217 (547—750 000) 126 000 (511—750 000) 0.07
Baseline CD4 count (cells/mm3) 197 (2—1300) 221 (2—1205) 0.62
Length of ART (months) 14 (12—38) 14 (12—72) 0.83
CI, confidence interval; ART, antiretroviral therapy.
Table 2 Optimal response rate according to age categories
Age category Optimal response
ratea n (%)
<15 years (n = 7) 1 (14.3%)
15—30 years (n = 60) 24 (40%)
31—45 years (n = 125) 46 (37%)
>45 years (n = 28) 18 (64.3%)
a p Value = 0.02 by Fisher’s exact test.The viral load ‘of interest’ was defined as the first viral
load available after 48 weeks of first ART regimen. The main
outcome variable was optimal response, defined as viral load
‘of interest’ of less than 400 copies. Viral load determination
was performed using Monitor PCR (Roche Laboratories).
Exposure variables included age, gender, length of ART, base-
line CD4 count, baseline viral load, region of the country,
mode of transmission, possible exposure to generic medica-
tions, and type of ARTregimen. Because of the retrospective
design, it was not possible to establish which patients were
actually exposed to generic medications. Based on the date
when generic medicines were introduced to these clinics, we
considered that a patient was possibly exposed to generic
medications when ART was initiated on or after December
2001.
Data were collected with a common instrument at all
sites. Statistical analysis was carried out using SAS 8.2 soft-
ware (SAS Institute, Cary, NC, USA). The association between
variables was explored using the Chi-square test and Fisher’s
exact test for categoric variables, andWilcoxon rank sum test
for numeric variables. A logistic regression model was built to
determine independent predictors of non-optimal response.
The Ethics Committee of the Fundacio´n Universitaria de
Ciencias de la Salud (FUCS) and the Research Center of
SaludCoop EPS approved the study.
Results
Two hundred and twenty patients were eligible for the study;
27 from the northern region, 84 from the central region, and
109 from the western region. One hundred and ninety-one
(86.8%) weremales and 29 (13.2%) were females. Themedian
age was 34 years (range 2—61 years). The most common
presumptive mechanism of transmission was sexual, with 146
patients (68.5%) reporting MSM (men who have sex with men)
activities, and 62 (29.1%) reporting exclusively heterosexual
activities. Only five cases (2.3%) were classified as secondary
to vertical transmission. The most common antiretroviral
regimen prescribed was zidovudine/lamivudine/indinavir
(56 patients, 25.5%), followed by zidovudine/lamivudine/
nelfinavir (44 patients, 20%), and zidovudine/lamivudine/
indinavir/ritonavir (31 patients, 14.1%). Themedian duration
of ART prior to the performance of the viral load of interestwas 14 months (range 12—72 months). The median baseline
viral load was 105 500 copies (5.02 log), and the median
baseline CD4 count was 206 cells/mm3 (range 2—1300 cells/
mm3). One hundred and four of 111 patients (93.7%) from the
central or northern regions had date of ART initiation avail-
able, which was used to establish possible exposure to gen-
eric medications. Accordingly, 57 (54.8%) of them were
possibly exposed to generic medications.
The observed overall optimal response rate was 40% (95%
confidence interval 34—46%). The best response rate was
observed for the central region (48%), followed by the north-
ern region (44%). The poorest response rate was observed for
the western region (33%). Younger age and western region of
the country were the only significant predictors of non-
optimal response in bivariate analysis (Tables 1 and 2).
Possible exposure to generic medications was not signifi-
cantly associated with a poorer response (51% response rate
in those unexposed vs. 43.8% response rate in those possibly
exposed, p = 0.46). Multivariate logistic regression analysis
confirmed younger age and geographic area as the only
independent predictors of non-optimal response (Table 3).
The results of multivariate analysis remained consistent after
excluding vertically infected children and after using base-
line viral load and CD4 counts as continuous variables.
Discussion
The estimated response rate in some areas of Colombia is
lower than that reported in recent studies from Africa and
Latin America. These reports have estimated response rates
of between 70% and 80%.6—8 Lack of adherence programs,
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Table 3 Multivariate logistic regression analysis assessing
independent predictors of non-optimal response to ART
Variable OR (95% CI) p Valuea
Male gender 2.409 (0.958—6.061) 0.0617
Younger age categoryb 1.996 (1.226—3.250) 0.0054
Baseline viral load
>100 000
1.206 (0.630—2.310) 0.5720
Baseline CD4
count <200
0.746 (0.388—1.436) 0.3810
Western region 1.490 (1.006—2.207) 0.0468
ART, antiretroviral therapy; OR, odds ratio; CI, confidence inter-
val.
a Wald test.
b Age category as specified in Table 2. OR is for each age
category (15 years decrement per category).limited healthcare provider expertise, an erratic supply of
medications, and high prevalence of viral resistance could
hypothetically explain our observed low response rate. Addi-
tionally, use of non-optimal regimens may be playing a role,
since the most common regimens prescribed in our study
were based on non-boosted protease inhibitors and on com-
binations associated with significant side effects and high pill
burden.9—11 The selection of antiretroviral regimens in
Colombia is at least partially influenced by the national list
of essential medications. At the time of the study, neither
efavirenz nor lopinavir—ritonavir were included in the essen-
tial medications list. This list has been modified since the
performance of the study, in part as a response to the
recently released national guidelines for the management
of HIV and AIDS.12 These guidelines also recommend the
inclusion of adherence programs at all the HIV care centers
across the country, and set clear indications for the consulta-
tion of infectious diseases experts.
Our data also suggest that there is a worse response in
younger patients as well as among those from the western
region of the country. The most likely explanation for the
association between age and optimal response is that age
might be acting as a surrogate marker of adherence, as
shown by previous investigations.13 Although we were
unable to extract a reliable measure of adherence from
the medical records, adherence is a well-established pre-
dictor of response.14—19 Colombian patients infected with
HIV could benefit from adherence programs paired with ART
provision.
Differential responses by geographic area could be
explained in part by differences in healthcare provider
expertise. Provider expertise has been clearly established
as a predictor of favorable outcomes in HIV-infected
patients.20 At the time of study conduction, two infectious
diseases experts were providing services to HIV-infected
patients affiliated to SaludCoop EPS, and both were located
at the central region clinic. For other areas, care was
provided by general physicians or by internal medicine
specialists, and only occasionally did the infectious diseases
experts intervene using the mechanism of telemedicine.
Improving healthcare provider expertise by education and
training initiatives might improve the outcome of Colom-
bian patients infected with HIV. Differential responses
might also be explained by differences in the availabilityand supply of medications, and differences in resistance of
circulating virus from one region to another. For the
patients affiliated to SaludCoop EPS, there is a central
pharmacy located in the capital city of Bogota´. From there,
medicines are distributed to other cities, which may not get
the medicines as steadily and as consistently as in the
capital city. Optimizing the distribution of medicines might
improve the observed response to ART in Colombia. No
statement can be made about the prevalence of resistant
virus because no systematic observations have been done
locally in that regard.
Conclusions about the response to ART in patients exposed
to generic medications cannot be drawn from our study. Our
results do not support the hypothesis that response is sub-
optimal with generic medications, but do not confirm that
generic medications are equivalent to original molecules
either. Of note, SaludCoop EPS provides only generics mar-
keted by a pharmaceutical company with products included
in the WHO prequalification list. Optimal response rate to
ART in Colombian patients exposed to other generics is
unknown.
This study has several limitations. The retrospective
design may compromise the quality of the information
creating the possibility of misclassification bias of expo-
sure. This was minimized by establishing clear definitions
before the initiation of the study and by the training of
data collectors. Misclassification of outcome is unlikely,
since we used up-to-date technology to perform viral load
testing and standardized definitions to classify optimal and
non-optimal response to therapy. The main possible bias of
our study is selection bias, since at the time of the study
there were no standardized criteria in the Obligatory
Health Plan (POS) to establish which patients required
the performance of a viral load test. Nevertheless, by
one and a half years of therapy initiation the majority
of individuals had had at least two follow-up viral load
tests done. Another reason for exclusion was that some
patients had been infected for several years and the
information about their response to initial ART regimens
was unavailable at the time of data collection. We think
there is no obvious reason to suspect that patients exposed
to one or another variable were differentially more or less
prone to exclusion from the study.
The Colombian government is currently leading a
national multi-sector response to optimize HIV manage-
ment. This initiative is based on the nationwide institution
of a programmatic management model21 intended to facil-
itate the adoption of the recently developed national HIV
guidelines.12 Political will and local legislation support this
initiative. Similar efforts by countries like Brazil22 and
Chile7 have favorably impacted the management of HIV
infection.
Our study supports the concept that antiretroviral provi-
sion programs should be paired whenever possible with
measures directed towards optimization of adherence,
provider expertise, medication quality, and a steady supply
of medications. Prospective studies are needed to further
evaluate the predictors of optimal response to ART in
Colombian patients, to validate the rate of optimal
response to ART found in our study, and to assess the impact
of the recently developed national guidelines on the quality
of HIV care.
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